Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects
Purpose To assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects. Methods Three phase 1 open-label studies were performed. Study 1: Japanese and Caucasian subjects received single doses of 25...
Uložené v:
| Vydané v: | European journal of clinical pharmacology Ročník 75; číslo 8; s. 1099 - 1108 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.08.2019
Springer Nature B.V |
| Predmet: | |
| ISSN: | 0031-6970, 1432-1041, 1432-1041 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Purpose
To assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects.
Methods
Three phase 1 open-label studies were performed. Study 1: Japanese and Caucasian subjects received single doses of 250, 500, or 1000 mg ivosidenib (NCT03071770). Part 1 of study 2 (a two-period crossover study): subjects received 500 mg ivosidenib after either an overnight fast or a high-fat meal. Subjects received 1000 mg ivosidenib after an overnight fast in the single period of part 2 (NCT02579707). Study 3: in period 1, subjects received 250 mg ivosidenib; then, in period 2, subjects received oral itraconazole (200 mg once daily) on days 1–18, plus 250 mg ivosidenib on day 5 (NCT02831972).
Results
Ivosidenib was well tolerated in all three studies. Study 1: pharmacokinetic profiles were generally comparable, although AUC and
C
max
were slightly lower in Japanese subjects than in Caucasian subjects, by ~ 30 and 17%, respectively. Study 2: AUC increased by ~ 25% and
C
max
by ~ 98%, when ivosidenib was administered with a high-fat meal compared with a fasted state. Study 3: co-administration of itraconazole increased ivosidenib AUC by 169% (90% CI 145–195) but had no effect on ivosidenib
C
max
.
Conclusions
No ivosidenib dose adjustment is deemed necessary for Japanese subjects. High-fat meals should be avoided when ivosidenib is taken with food. When co-administered with strong CYP3A4 inhibitors, monitoring for QT interval prolongation (a previously defined adverse event of interest) is recommended and an ivosidenib dose interruption or reduction may be considered.
ClinicalTrials.gov
NCT03071770, NCT02579707, and NCT02831972. |
|---|---|
| AbstractList | To assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects.
Three phase 1 open-label studies were performed. Study 1: Japanese and Caucasian subjects received single doses of 250, 500, or 1000 mg ivosidenib (NCT03071770). Part 1 of study 2 (a two-period crossover study): subjects received 500 mg ivosidenib after either an overnight fast or a high-fat meal. Subjects received 1000 mg ivosidenib after an overnight fast in the single period of part 2 (NCT02579707). Study 3: in period 1, subjects received 250 mg ivosidenib; then, in period 2, subjects received oral itraconazole (200 mg once daily) on days 1-18, plus 250 mg ivosidenib on day 5 (NCT02831972).
Ivosidenib was well tolerated in all three studies. Study 1: pharmacokinetic profiles were generally comparable, although AUC and C
were slightly lower in Japanese subjects than in Caucasian subjects, by ~ 30 and 17%, respectively. Study 2: AUC increased by ~ 25% and C
by ~ 98%, when ivosidenib was administered with a high-fat meal compared with a fasted state. Study 3: co-administration of itraconazole increased ivosidenib AUC by 169% (90% CI 145-195) but had no effect on ivosidenib C
.
No ivosidenib dose adjustment is deemed necessary for Japanese subjects. High-fat meals should be avoided when ivosidenib is taken with food. When co-administered with strong CYP3A4 inhibitors, monitoring for QT interval prolongation (a previously defined adverse event of interest) is recommended and an ivosidenib dose interruption or reduction may be considered. CLINICALTRIALS.GOV : NCT03071770, NCT02579707, and NCT02831972. PurposeTo assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects.MethodsThree phase 1 open-label studies were performed. Study 1: Japanese and Caucasian subjects received single doses of 250, 500, or 1000 mg ivosidenib (NCT03071770). Part 1 of study 2 (a two-period crossover study): subjects received 500 mg ivosidenib after either an overnight fast or a high-fat meal. Subjects received 1000 mg ivosidenib after an overnight fast in the single period of part 2 (NCT02579707). Study 3: in period 1, subjects received 250 mg ivosidenib; then, in period 2, subjects received oral itraconazole (200 mg once daily) on days 1–18, plus 250 mg ivosidenib on day 5 (NCT02831972).ResultsIvosidenib was well tolerated in all three studies. Study 1: pharmacokinetic profiles were generally comparable, although AUC and Cmax were slightly lower in Japanese subjects than in Caucasian subjects, by ~ 30 and 17%, respectively. Study 2: AUC increased by ~ 25% and Cmax by ~ 98%, when ivosidenib was administered with a high-fat meal compared with a fasted state. Study 3: co-administration of itraconazole increased ivosidenib AUC by 169% (90% CI 145–195) but had no effect on ivosidenib Cmax.ConclusionsNo ivosidenib dose adjustment is deemed necessary for Japanese subjects. High-fat meals should be avoided when ivosidenib is taken with food. When co-administered with strong CYP3A4 inhibitors, monitoring for QT interval prolongation (a previously defined adverse event of interest) is recommended and an ivosidenib dose interruption or reduction may be considered.ClinicalTrials.govNCT03071770, NCT02579707, and NCT02831972. To assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects.PURPOSETo assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects.Three phase 1 open-label studies were performed. Study 1: Japanese and Caucasian subjects received single doses of 250, 500, or 1000 mg ivosidenib (NCT03071770). Part 1 of study 2 (a two-period crossover study): subjects received 500 mg ivosidenib after either an overnight fast or a high-fat meal. Subjects received 1000 mg ivosidenib after an overnight fast in the single period of part 2 (NCT02579707). Study 3: in period 1, subjects received 250 mg ivosidenib; then, in period 2, subjects received oral itraconazole (200 mg once daily) on days 1-18, plus 250 mg ivosidenib on day 5 (NCT02831972).METHODSThree phase 1 open-label studies were performed. Study 1: Japanese and Caucasian subjects received single doses of 250, 500, or 1000 mg ivosidenib (NCT03071770). Part 1 of study 2 (a two-period crossover study): subjects received 500 mg ivosidenib after either an overnight fast or a high-fat meal. Subjects received 1000 mg ivosidenib after an overnight fast in the single period of part 2 (NCT02579707). Study 3: in period 1, subjects received 250 mg ivosidenib; then, in period 2, subjects received oral itraconazole (200 mg once daily) on days 1-18, plus 250 mg ivosidenib on day 5 (NCT02831972).Ivosidenib was well tolerated in all three studies. Study 1: pharmacokinetic profiles were generally comparable, although AUC and Cmax were slightly lower in Japanese subjects than in Caucasian subjects, by ~ 30 and 17%, respectively. Study 2: AUC increased by ~ 25% and Cmax by ~ 98%, when ivosidenib was administered with a high-fat meal compared with a fasted state. Study 3: co-administration of itraconazole increased ivosidenib AUC by 169% (90% CI 145-195) but had no effect on ivosidenib Cmax.RESULTSIvosidenib was well tolerated in all three studies. Study 1: pharmacokinetic profiles were generally comparable, although AUC and Cmax were slightly lower in Japanese subjects than in Caucasian subjects, by ~ 30 and 17%, respectively. Study 2: AUC increased by ~ 25% and Cmax by ~ 98%, when ivosidenib was administered with a high-fat meal compared with a fasted state. Study 3: co-administration of itraconazole increased ivosidenib AUC by 169% (90% CI 145-195) but had no effect on ivosidenib Cmax.No ivosidenib dose adjustment is deemed necessary for Japanese subjects. High-fat meals should be avoided when ivosidenib is taken with food. When co-administered with strong CYP3A4 inhibitors, monitoring for QT interval prolongation (a previously defined adverse event of interest) is recommended and an ivosidenib dose interruption or reduction may be considered. CLINICALTRIALS.GOV : NCT03071770, NCT02579707, and NCT02831972.CONCLUSIONSNo ivosidenib dose adjustment is deemed necessary for Japanese subjects. High-fat meals should be avoided when ivosidenib is taken with food. When co-administered with strong CYP3A4 inhibitors, monitoring for QT interval prolongation (a previously defined adverse event of interest) is recommended and an ivosidenib dose interruption or reduction may be considered. CLINICALTRIALS.GOV : NCT03071770, NCT02579707, and NCT02831972. Purpose To assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy subjects. Methods Three phase 1 open-label studies were performed. Study 1: Japanese and Caucasian subjects received single doses of 250, 500, or 1000 mg ivosidenib (NCT03071770). Part 1 of study 2 (a two-period crossover study): subjects received 500 mg ivosidenib after either an overnight fast or a high-fat meal. Subjects received 1000 mg ivosidenib after an overnight fast in the single period of part 2 (NCT02579707). Study 3: in period 1, subjects received 250 mg ivosidenib; then, in period 2, subjects received oral itraconazole (200 mg once daily) on days 1–18, plus 250 mg ivosidenib on day 5 (NCT02831972). Results Ivosidenib was well tolerated in all three studies. Study 1: pharmacokinetic profiles were generally comparable, although AUC and C max were slightly lower in Japanese subjects than in Caucasian subjects, by ~ 30 and 17%, respectively. Study 2: AUC increased by ~ 25% and C max by ~ 98%, when ivosidenib was administered with a high-fat meal compared with a fasted state. Study 3: co-administration of itraconazole increased ivosidenib AUC by 169% (90% CI 145–195) but had no effect on ivosidenib C max . Conclusions No ivosidenib dose adjustment is deemed necessary for Japanese subjects. High-fat meals should be avoided when ivosidenib is taken with food. When co-administered with strong CYP3A4 inhibitors, monitoring for QT interval prolongation (a previously defined adverse event of interest) is recommended and an ivosidenib dose interruption or reduction may be considered. ClinicalTrials.gov NCT03071770, NCT02579707, and NCT02831972. |
| Author | Dai, David Zacher, Jeffrey Nabhan, Salah Liu, Hua Vutikullird, Apinya Agresta, Samuel Prakash, Chandra Yang, Hua Liu, Guowen Bowden, Chris Hickman, Denice Fan, Bin |
| Author_xml | – sequence: 1 givenname: David surname: Dai fullname: Dai, David organization: Agios Pharmaceuticals, Inc – sequence: 2 givenname: Hua surname: Yang fullname: Yang, Hua organization: Agios Pharmaceuticals, Inc – sequence: 3 givenname: Salah surname: Nabhan fullname: Nabhan, Salah organization: Agios Pharmaceuticals, Inc – sequence: 4 givenname: Hua surname: Liu fullname: Liu, Hua organization: Agios Pharmaceuticals, Inc – sequence: 5 givenname: Denice surname: Hickman fullname: Hickman, Denice organization: Agios Pharmaceuticals, Inc – sequence: 6 givenname: Guowen surname: Liu fullname: Liu, Guowen organization: Agios Pharmaceuticals, Inc – sequence: 7 givenname: Jeffrey surname: Zacher fullname: Zacher, Jeffrey organization: Celerion – sequence: 8 givenname: Apinya surname: Vutikullird fullname: Vutikullird, Apinya organization: WCCT Global – sequence: 9 givenname: Chandra surname: Prakash fullname: Prakash, Chandra organization: Agios Pharmaceuticals, Inc – sequence: 10 givenname: Samuel surname: Agresta fullname: Agresta, Samuel organization: Agios Pharmaceuticals, Inc., Infinity Pharmaceuticals, Inc – sequence: 11 givenname: Chris surname: Bowden fullname: Bowden, Chris organization: Agios Pharmaceuticals, Inc – sequence: 12 givenname: Bin surname: Fan fullname: Fan, Bin email: bin.fan@agios.com organization: Agios Pharmaceuticals, Inc |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31011758$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kTtvFDEURi0URDYLf4ACWaKhyMD1Y14lisJDikQDtWV7rjNeZu3F9kQKvx4nG0BKkeo259zXd0ZOQgxIyGsG7xlA_yEDcD40wMYGeNeLpntGNkwK3jCQ7IRsAARrurGHU3KW8w6AtSOIF-RUMGCsb4cN8ZfOoS00OupL0jYG_TsueE5djNM51WGiWObgLY3JX_tAY6BlRnqYddpX_KcPWLzN9w1uYvYTBm9oBWfUS5lvaV7Nrk7IL8lzp5eMrx7qlvz4dPn94ktz9e3z14uPV42VbCyNEPWmSRprJO-m3slB6skOAgUATL0UTlhjsbOGjcZpjXxwIE3bdXxoOWqxJe-OfQ8p_loxF7X32eKy6IBxzYpzJljL2_qoLXn7CN3FNYW63R3FhZCDaCv15oFazR4ndUh-r9Ot-vvECvAjYFPMOaH7hzBQd0mpY1KqJqXuk1JdlYZHkvVFFx9DjcEvT6viqOY6J1xj-r_2E9YfwjunSA |
| CitedBy_id | crossref_primary_10_1007_s00280_019_03793_7 crossref_primary_10_1097_FTD_0000000000000952 crossref_primary_10_1016_S2352_3026_22_00073_4 crossref_primary_10_7759_cureus_44802 crossref_primary_10_1016_S2352_3026_21_00232_5 crossref_primary_10_2147_DDDT_S243760 crossref_primary_10_1002_cpdd_1067 crossref_primary_10_1111_cts_12959 crossref_primary_10_3390_pharmaceutics14112493 crossref_primary_10_1007_s00277_020_04186_0 crossref_primary_10_1007_s12281_020_00386_3 crossref_primary_10_2147_BLCTT_S236446 crossref_primary_10_1007_s00280_020_04064_6 crossref_primary_10_1177_10781552231171079 crossref_primary_10_1002_cpdd_821 crossref_primary_10_1007_s11523_023_01002_3 crossref_primary_10_1007_s00228_023_03591_4 crossref_primary_10_3389_fphar_2021_743411 crossref_primary_10_1093_chromsci_bmad082 crossref_primary_10_1124_dmd_120_000234 crossref_primary_10_1016_j_jpba_2020_113353 crossref_primary_10_1080_14656566_2023_2272659 crossref_primary_10_1007_s00280_020_04148_3 crossref_primary_10_1007_s40268_021_00352_5 crossref_primary_10_1080_14656566_2020_1806822 |
| Cites_doi | 10.1016/j.ccr.2010.01.020 10.1093/annonc/mdw013 10.1023/A:1016473601633 10.1093/cid/cis773 10.1016/j.jchromb.2016.03.039 10.1021/acsmedchemlett.7b00421 10.1056/NEJMoa0903840 10.1038/sj.clpt.6100482 10.1038/embor.2011.43 10.1038/nature08617 10.1158/1078-0432.CCR-16-2628 10.1146/annurev-cancerbio-050216-122051 10.1007/s00277-018-3304-y 10.1056/NEJMoa1716984 10.1016/j.ccr.2010.12.014 10.1007/s40265-018-0978-3 10.1002/ajh.24072 10.3109/10428194.2012.695359 10.1309/AJCPD7NR2RMNQDVF 10.1007/s00280-019-03793-7 10.1182/blood.V126.23.1310.1310 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2019 European Journal of Clinical Pharmacology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2019 – notice: European Journal of Clinical Pharmacology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s00228-019-02673-6 |
| DatabaseName | Springer Nature OA/Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Academic Middle East (New) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-1041 |
| EndPage | 1108 |
| ExternalDocumentID | 31011758 10_1007_s00228_019_02673_6 |
| Genre | Randomized Controlled Trial Journal Article Clinical Trial, Phase I |
| GrantInformation_xml | – fundername: Agios Pharmaceuticals, Inc. grantid: n/a |
| GroupedDBID | --- -4W -56 -5G -BR -EM -~C .86 .VR 04C 06C 06D 0R~ 0VY 199 1N0 203 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 36B 4.4 406 408 409 40D 40E 5RE 5VS 67N 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8FW 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABUWG ABWNU ABXPI ACAOD ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFKRA AFLOW AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI C6C CCPQU CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECT EIHBH EIOEI EJD EMB EMOBN EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M4Y MA- MK0 N9A NAPCQ NB0 NPVJJ NQJWS NU0 O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV ROL RPX RRX RSV S16 S27 S3A S3B SAP SBL SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z7V Z7W Z81 Z82 Z83 Z87 Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZMTXR ZOVNA ~EX ~KM -Y2 .GJ 1SB 2.D 28- 2P1 2VQ 3O- 3SX 53G 5QI AANXM AAPKM AARHV AAYTO AAYXX ABBRH ABDBE ABFSG ABQSL ABRTQ ABULA ACBXY ACSTC ADHKG ADYPR AEBTG AEFIE AEKMD AEZWR AFDYV AFDZB AFEXP AFFHD AFFNX AFGCZ AFHIU AFOHR AGGDS AGJBK AGQPQ AHPBZ AHWEU AIXLP AJBLW ATHPR AYFIA BBWZM CAG CITATION COF EN4 H13 KOW N2Q NDZJH O9- PHGZM PHGZT PJZUB PPXIY R4E RNI RZK S1Z S26 S28 SBY SCLPG T16 WK6 Y6R ZGI ZXP 3V. AAYOK CGR CUY CVF ECM EIF NPM RIG 7TK 7U9 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c419t-33228d4bcb426d7f484adc83e3000d743f3cbce6cb19bfaae28f04b5662852ea3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 23 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000475794400008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0031-6970 1432-1041 |
| IngestDate | Sat Sep 27 23:56:08 EDT 2025 Tue Dec 02 16:06:50 EST 2025 Wed Feb 19 02:32:14 EST 2025 Sat Nov 29 02:59:37 EST 2025 Tue Nov 18 21:01:40 EST 2025 Fri Feb 21 02:34:23 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Isocitrate dehydrogenase 1 inhibitor CYP3A4 inhibitors Drug interaction Food effect Pharmacokinetics Ivosidenib |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c419t-33228d4bcb426d7f484adc83e3000d743f3cbce6cb19bfaae28f04b5662852ea3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1007/s00228-019-02673-6 |
| PMID | 31011758 |
| PQID | 2212334835 |
| PQPubID | 47171 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2213152514 proquest_journals_2212334835 pubmed_primary_31011758 crossref_primary_10_1007_s00228_019_02673_6 crossref_citationtrail_10_1007_s00228_019_02673_6 springer_journals_10_1007_s00228_019_02673_6 |
| PublicationCentury | 2000 |
| PublicationDate | 20190801 2019-8-00 2019-Aug |
| PublicationDateYYYYMMDD | 2019-08-01 |
| PublicationDate_xml | – month: 8 year: 2019 text: 20190801 day: 1 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | European journal of clinical pharmacology |
| PublicationTitleAbbrev | Eur J Clin Pharmacol |
| PublicationTitleAlternate | Eur J Clin Pharmacol |
| PublicationYear | 2019 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Dang, White, Gross, Bennett, Bittinger, Driggers, Fantin, Jang, Jin, Keenan, Marks, Prins, Ward, Yen, Liau, Rabinowitz, Cantley, Thompson, Vander Heiden, Su (CR1) 2009; 462 Stein, Yen (CR5) 2017; 1 Zhou, Jiang, Shang, Wang, Huang, Zhou (CR12) 2012; 53 Xu, Yang, Liu, Yang, Wang, Kim, Ito, Yang, Xiao, Liu, Jiang, Liu, Zhang, Wang, Frye, Zhang, Xu, Lei, Guan, Zhao, Xiong (CR4) 2011; 19 Popovici-Muller, Lemieux, Artin, Saunders, Salituro, Travins, Cianchetta, Cai, Zhou, Cui, Chen, Straley, Tobin, Wang, David, Penard-Lacronique, Quivoron, Saada, de Botton, Gross, Dang, Yang, Utley, Chen, Kim, Jin, Gu, Yao, Luo, Lv, Fang, Yan, Olaharski, Silverman, Biller, Su, Yen (CR6) 2018; 9 DiNardo, Stein, de Botton, Roboz, Altman, Mims, Swords, Collins, Mannis, Pollyea, Donnellan, Fathi, Pigneux, Erba, Prince, Stein, Uy, Foran, Traer, Stuart, Arellano, Slack, Sekeres, Willekens, Choe, Wang, Zhang, Yen, Kapsalis, Yang, Dai, Fan, Goldwasser, Liu, Agresta, Wu, Attar, Tallman, Stone, Kantarjian (CR15) 2018; 378 CR18 Chowdhury, Yeoh, Tian, Hillringhaus, Bagg, Rose, Leung, Li, Woon, Yang, McDonough, King, Clifton, Klose, Claridge, Ratcliffe, Schofield, Kawamura (CR3) 2011; 12 Patel, Ravandi, Ma, Paladugu, Barkoh, Medeiros, Luthra (CR9) 2011; 135 Dhillon (CR16) 2018; 78 CR24 Mardis, Ding, Dooling, Larson, McLellan, Chen, Koboldt, Fulton, Delehaunty, McGrath, Fulton, Locke, Magrini, Abbott, Vickery, Reed, Robinson, Wylie, Smith, Carmichael, Eldred, Harris, Walker, Peck, Du, Dukes, Sanderson, Brummett, Clark, McMichael, Meyer, Schindler, Pohl, Wallis, Shi, Lin, Schmidt, Tang, Haipek, Wiechert, Ivy, Kalicki, Elliott, Ries, Payton, Westervelt, Tomasson, Watson, Baty, Heath, Shannon, Nagarajan, Link, Walter, Graubert, DiPersio, Wilson, Ley (CR8) 2009; 361 Feng, Guo, Chen, Wang, Cheng, Tang (CR11) 2012; 2 Xu, Li, Lv, Jing, Xu, Li, Yao, Chen, Huang, Wang, Yu (CR13) 2017; 23 Liang, Van Parys, Ding, Zeng, Bi, Dorshort, McKnight, Milanowski, Mao, Chen, Ware, Dean, Hop, Deng (CR21) 2016; 1020 CR20 Myrand, Sekiguchi, Man, Lin, Tzeng, Teng, Hee, Garrett, Kikkawa, Lin, Eddy, Dostalik, Mount, Azuma, Fujio, Jang, Shin, Bleavins, Williams, Paulauskis, Wilner (CR23) 2008; 84 DiNardo, Ravandi, Agresta, Konopleva, Takahashi, Kadia, Routbort, Patel, Mark, Pierce, Garcia-Manero, Cortes, Kantarjian (CR10) 2015; 90 Yu, Amidon, Polli, Zhao, Mehta, Conner, Shah, Lesko, Chen, Lee, Hussain (CR17) 2002; 19 Ward, Patel, Wise, Abdel-Wahab, Bennett, Coller, Cross, Fantin, Hedvat, Perl, Rabinowitz, Carroll, Su, Sharp, Levine, Thompson (CR2) 2010; 17 Megias-Vericat, Martinez-Cuadron, Sanz, Montesinos (CR14) 2018; 97 Dang, Yen, Attar (CR7) 2016; 27 Pagano, Caira, Candoni, Aversa, Castagnola, Caramatti, Cattaneo, Delia, De Paolis, Di Blasi, Di Caprio, Fanci, Garzia, Martino, Melillo, Mitra, Nadali, Nosari, Picardi, Potenza, Salutari, Trecarichi, Tumbarello, Verga, Vianelli, Busca (CR19) 2012; 55 Fan, Le, Manyak, Liu, Prahl, Bowden, Biller, Agresta, Yang (CR22) 2015; 126 JH Feng (2673_CR11) 2012; 2 2673_CR18 ER Mardis (2673_CR8) 2009; 361 L Pagano (2673_CR19) 2012; 55 Q Xu (2673_CR13) 2017; 23 L Dang (2673_CR1) 2009; 462 CD DiNardo (2673_CR15) 2018; 378 2673_CR24 KG Zhou (2673_CR12) 2012; 53 PS Ward (2673_CR2) 2010; 17 SP Myrand (2673_CR23) 2008; 84 E Stein (2673_CR5) 2017; 1 JE Megias-Vericat (2673_CR14) 2018; 97 KP Patel (2673_CR9) 2011; 135 S Dhillon (2673_CR16) 2018; 78 R Chowdhury (2673_CR3) 2011; 12 J Popovici-Muller (2673_CR6) 2018; 9 L Dang (2673_CR7) 2016; 27 2673_CR20 CD DiNardo (2673_CR10) 2015; 90 B Fan (2673_CR22) 2015; 126 W Xu (2673_CR4) 2011; 19 LX Yu (2673_CR17) 2002; 19 X Liang (2673_CR21) 2016; 1020 |
| References_xml | – volume: 17 start-page: 225 issue: 3 year: 2010 end-page: 234 ident: CR2 article-title: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.01.020 – ident: CR18 – volume: 27 start-page: 599 issue: 4 year: 2016 end-page: 608 ident: CR7 article-title: IDH mutations in cancer and progress toward development of targeted therapeutics publication-title: Ann Oncol doi: 10.1093/annonc/mdw013 – volume: 19 start-page: 921 issue: 7 year: 2002 end-page: 925 ident: CR17 article-title: Biopharmaceutics classification system: the scientific basis for biowaiver extensions publication-title: Pharm Res doi: 10.1023/A:1016473601633 – volume: 55 start-page: 1515 issue: 11 year: 2012 end-page: 1521 ident: CR19 article-title: Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry publication-title: Clin Infect Dis doi: 10.1093/cid/cis773 – volume: 1020 start-page: 111 year: 2016 end-page: 119 ident: CR21 article-title: Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry publication-title: J Chromatogr B Anal Technol Biomed Life Sci doi: 10.1016/j.jchromb.2016.03.039 – volume: 9 start-page: 300 issue: 4 year: 2018 end-page: 305 ident: CR6 article-title: Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers publication-title: ACS Med Chem Lett doi: 10.1021/acsmedchemlett.7b00421 – volume: 361 start-page: 1058 issue: 11 year: 2009 end-page: 1066 ident: CR8 article-title: Recurring mutations found by sequencing an acute myeloid leukemia genome publication-title: N Engl J Med doi: 10.1056/NEJMoa0903840 – volume: 126 start-page: Abstract 1310 issue: 23 year: 2015 ident: CR22 article-title: Longitudinal pharmacokinetic/pharmacodynamic profile of AG-120, a potent inhibitor of the IDH1 mutant protein, in a phase 1 study of IDH1-mutant advanced hematologic malignancies publication-title: Blood – volume: 84 start-page: 347 issue: 3 year: 2008 end-page: 361 ident: CR23 article-title: Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100482 – volume: 2 start-page: 254 issue: 4 year: 2012 end-page: 264 ident: CR11 article-title: Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis publication-title: Am J Blood Res – volume: 12 start-page: 463 issue: 5 year: 2011 end-page: 469 ident: CR3 article-title: The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases publication-title: EMBO Rep doi: 10.1038/embor.2011.43 – volume: 462 start-page: 739 issue: 7274 year: 2009 end-page: 744 ident: CR1 article-title: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate publication-title: Nature doi: 10.1038/nature08617 – volume: 23 start-page: 4511 issue: 15 year: 2017 end-page: 4522 ident: CR13 article-title: Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-2628 – volume: 1 start-page: 379 issue: 1 year: 2017 end-page: 401 ident: CR5 article-title: Targeted differentiation therapy with mutant IDH inhibitors: early experiences and parallels with other differentiation agents publication-title: Ann Rev Cancer Biol doi: 10.1146/annurev-cancerbio-050216-122051 – volume: 97 start-page: 1115 issue: 7 year: 2018 end-page: 1153 ident: CR14 article-title: Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review publication-title: Ann Hematol doi: 10.1007/s00277-018-3304-y – volume: 378 start-page: 2386 issue: 25 year: 2018 end-page: 2398 ident: CR15 article-title: Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML publication-title: N Engl J Med doi: 10.1056/NEJMoa1716984 – volume: 19 start-page: 17 issue: 1 year: 2011 end-page: 30 ident: CR4 article-title: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.12.014 – volume: 78 start-page: 1509 issue: 14 year: 2018 end-page: 1516 ident: CR16 article-title: Ivosidenib: first global approval publication-title: Drugs doi: 10.1007/s40265-018-0978-3 – ident: CR24 – volume: 90 start-page: 732 issue: 8 year: 2015 end-page: 736 ident: CR10 article-title: Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML publication-title: Am J Hematol doi: 10.1002/ajh.24072 – volume: 53 start-page: 2423 issue: 12 year: 2012 end-page: 2429 ident: CR12 article-title: Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis publication-title: Leuk Lymphoma doi: 10.3109/10428194.2012.695359 – ident: CR20 – volume: 135 start-page: 35 issue: 1 year: 2011 end-page: 45 ident: CR9 article-title: Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features publication-title: Am J Clin Pathol doi: 10.1309/AJCPD7NR2RMNQDVF – volume: 53 start-page: 2423 issue: 12 year: 2012 ident: 2673_CR12 publication-title: Leuk Lymphoma doi: 10.3109/10428194.2012.695359 – volume: 378 start-page: 2386 issue: 25 year: 2018 ident: 2673_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa1716984 – volume: 19 start-page: 17 issue: 1 year: 2011 ident: 2673_CR4 publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.12.014 – volume: 9 start-page: 300 issue: 4 year: 2018 ident: 2673_CR6 publication-title: ACS Med Chem Lett doi: 10.1021/acsmedchemlett.7b00421 – volume: 23 start-page: 4511 issue: 15 year: 2017 ident: 2673_CR13 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-2628 – volume: 361 start-page: 1058 issue: 11 year: 2009 ident: 2673_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa0903840 – ident: 2673_CR18 doi: 10.1007/s00280-019-03793-7 – volume: 126 start-page: Abstract 1310 issue: 23 year: 2015 ident: 2673_CR22 publication-title: Blood doi: 10.1182/blood.V126.23.1310.1310 – volume: 90 start-page: 732 issue: 8 year: 2015 ident: 2673_CR10 publication-title: Am J Hematol doi: 10.1002/ajh.24072 – volume: 17 start-page: 225 issue: 3 year: 2010 ident: 2673_CR2 publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.01.020 – volume: 78 start-page: 1509 issue: 14 year: 2018 ident: 2673_CR16 publication-title: Drugs doi: 10.1007/s40265-018-0978-3 – volume: 2 start-page: 254 issue: 4 year: 2012 ident: 2673_CR11 publication-title: Am J Blood Res – volume: 19 start-page: 921 issue: 7 year: 2002 ident: 2673_CR17 publication-title: Pharm Res doi: 10.1023/A:1016473601633 – volume: 27 start-page: 599 issue: 4 year: 2016 ident: 2673_CR7 publication-title: Ann Oncol doi: 10.1093/annonc/mdw013 – ident: 2673_CR24 – volume: 1020 start-page: 111 year: 2016 ident: 2673_CR21 publication-title: J Chromatogr B Anal Technol Biomed Life Sci doi: 10.1016/j.jchromb.2016.03.039 – volume: 1 start-page: 379 issue: 1 year: 2017 ident: 2673_CR5 publication-title: Ann Rev Cancer Biol doi: 10.1146/annurev-cancerbio-050216-122051 – volume: 135 start-page: 35 issue: 1 year: 2011 ident: 2673_CR9 publication-title: Am J Clin Pathol doi: 10.1309/AJCPD7NR2RMNQDVF – volume: 462 start-page: 739 issue: 7274 year: 2009 ident: 2673_CR1 publication-title: Nature doi: 10.1038/nature08617 – volume: 97 start-page: 1115 issue: 7 year: 2018 ident: 2673_CR14 publication-title: Ann Hematol doi: 10.1007/s00277-018-3304-y – volume: 12 start-page: 463 issue: 5 year: 2011 ident: 2673_CR3 publication-title: EMBO Rep doi: 10.1038/embor.2011.43 – volume: 84 start-page: 347 issue: 3 year: 2008 ident: 2673_CR23 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100482 – ident: 2673_CR20 – volume: 55 start-page: 1515 issue: 11 year: 2012 ident: 2673_CR19 publication-title: Clin Infect Dis doi: 10.1093/cid/cis773 |
| SSID | ssj0015903 |
| Score | 2.3773599 |
| Snippet | Purpose
To assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in... To assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in healthy... PurposeTo assess the effect of ethnicity, food, and itraconazole (strong CYP3A4 inhibitor) on the pharmacokinetics of ivosidenib after single oral doses in... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1099 |
| SubjectTerms | Administration, Oral Adult Antifungal agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Area Under Curve Asian Continental Ancestry Group Biomedical and Life Sciences Biomedicine Clinical trials Cross-Over Studies Cytochrome P-450 CYP3A Inhibitors - pharmacology Dehydrogenases Dose-Response Relationship, Drug Drug dosages Drug Interactions - ethnology Ethnicity FDA approval Female Food Food-Drug Interactions - ethnology Gene expression Glycine - administration & dosage Glycine - adverse effects Glycine - analogs & derivatives Glycine - pharmacokinetics Healthy Volunteers Humans Itraconazole Itraconazole - administration & dosage Itraconazole - pharmacology Leukemia, Myeloid, Acute - drug therapy Long QT Syndrome - diagnosis Long QT Syndrome - epidemiology Long QT Syndrome - etiology Male Metabolism Middle Aged Minority & ethnic groups Mutation Patients Pharmaceuticals Pharmacokinetics Pharmacokinetics and Disposition Pharmacology/Toxicology Pyridines - administration & dosage Pyridines - adverse effects Pyridines - pharmacokinetics |
| SummonAdditionalLinks | – databaseName: SpringerLink Contemporary (1997 - Present) dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5B4cCFlndKQUZCvZBIie0k9rFCVJyqFRTUW2Q7joionGqTrbT8-o6dxwoVkMo1mUwse8bzxZP5BuA95UWqUjRexNo64dzWiaCG4YLkgmphqaIqNJsoz87ExYVcTUVh_fy3-5ySDDv1UuwWqFrw01cmvmsSS4r78ADDnfDu-OXr9yV3kMt0otrNkkKW6VQq82cdv4ejWxjzVn40hJ3T_f8b8AE8nmAmORnt4gncs-4pHK9GnuptTM53ZVd9TI7JasdgvX0G7chpTLqGtMMaLzv1q7u0MWm6ro6JcjWxww_XGjL21SKdIwgkydWk5SdCV685KLjufEdQ12qCgmPZ5Zb0G-0PgPrn8O300_nHz8nUkyExPJNDwnADEDXXRmNor8uGC65qI5hluLfWCEcaZrSxhdGZ1I1Sloom5RpBIxU5tYq9gD3XOfsKiMyZktLKQhWU16WWWV4rUVLV6LyhSkWQzUtTmYmw3PfNuKwWquUwwxXOcBVmuCoi-LA8czXSdfxT-mhe8Wpy3b6iPpgzjsg0gnfLbXQ6n0lRznabIMN846iMR_BytJTldYiXPf2piCCezWKn_O9jObyb-Gt4RINleQM7gr1hvbFv4KG5Htp-_TY4xA1eOQOl priority: 102 providerName: Springer Nature |
| Title | Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects |
| URI | https://link.springer.com/article/10.1007/s00228-019-02673-6 https://www.ncbi.nlm.nih.gov/pubmed/31011758 https://www.proquest.com/docview/2212334835 https://www.proquest.com/docview/2213152514 |
| Volume | 75 |
| WOSCitedRecordID | wos000475794400008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: Springer Standard Collection customDbUrl: eissn: 1432-1041 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0015903 issn: 0031-6970 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwEB3RLQcu5RsCpTIS6oVEJLaT2CcEqBWn1Wop1d4if0WNqJJlk620_fXYjndXqKIXLpGSOI6lGY9fPJn3AD5gWqQitc5rsbZMKDU6YVgRa5CcYckMFlh4sYlyOmWLBZ-FDbc-_Fa5jYk-UOtOuT3yT9jFWEItYPi8_J041SiXXQ0SGgdw6JjK6AQOv55NZ_NdHiHnaaDdzZKCl2kom_HFc576xX5K88SpMJGk-HtpuoM37-RK_RJ0_vh_B_8EjgL4RF9Gb3kKD0z7DE5nI3v1JkYX-2KsPkanaLbntd48h2ZkOkZdjZphZS-34ra7NjGqu07HSLQameGqbRQa1bZQ1yILL9Ey9PLLAlrXs-_gpnM6oW0jkW04FmNuUL-WbluofwE_z88uvn1PglJDomjGh4TYsMA0lUraBV-XNWVUaMWIITbiagtSaqKkMoWSGZe1EAazOqXSQknMcmwEeQmTtmvNa0A8J4JzwwtRYKpLybNcC1ZiUcu8xkJEkG2NVKlAY-7UNK6rHQGzN2xlDVt5w1ZFBB93zyxHEo97Wx9vjViFCd1XewtG8H53205Fl18RrenWvg1xclIZjeDV6DO711kU7UhRWQTx1on2nf97LG_uH8tbeIS9Azs_PobJsFqbd_BQ3QxNvzqBg3J-6Y6L0h_ZSZge9mz-4_IPkocSww |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VggQX3o-FAkaCXkhE4jiJfUAIAVWrltUKLai3YDuOiKiSZZMtWn4Uv5Gx81ihit564Jo4E8v-PB4_5vsAnlOWBDJA8GKsrXzGTO5zqiPskJhTxQ2VVDqxiXQ65cfHYrYFv4dcGHutcvCJzlHntbZ75K-o9bERw4DhzeKHb1Wj7OnqIKHRweLQrH_ikq15ffAe-_cFpXsf5u_2_V5VwNcsFK0fIYR5zpRWODnlacE4k7nmkYnQO-Q4oRaRVtokWoVCFVIayouAKQx7KI-pkRHavQSX0Y-H9gpZ-unLeGoRi6An-Q39RKRBn6TjUvUc0Qwu3IVvNZ8iP_l7IjwT3Z45mXUT3t6N_62pbsL1PrQmb7uxcAu2THUbdmcdN_faI_NNqlnjkV0y27B2r-9A2fE4k7ogZbvEx5X8VZ8YjxR1nXtEVjkx7beq1KTTEiN1RTB4JoveyncM161lZ-C0tiqoVakIFuxSTdekWSm76dXchc8X0gz3YLuqK_MAiIgjKYQRiUwoy1MlwjiXPKWyUHFBpZxAOIAi0z1Ju9UKOclGemkHpAyBlDkgZckEXo7fLDqKknNL7wygyXp31WQbxEzg2fgaHY09PZKVqVeuTGTFskI2gfsdRsff4RrBUr7yCXgDaDfG_12Xh-fX5Slc3Z9_PMqODqaHj-AadYPHjqEd2G6XK_MYrujTtmyWT9wwJPD1osH8Byaxa8Q |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLUJceD8CBYwEvZCoieMk9gEhoF1RFa1WqEi9pbbjiIgqWTbZouWn8esY57VCFb31wDVxJpb9eTx-zPcBvKIs9qWP4MVYW3mMmczjVIfYIRGnihsqqWzFJpLZjJ-ciPkW_B5yYey1ysEnto46q7TdI9-j1seGDAOGvby_FjHfn75b_PCsgpQ9aR3kNDqIHJn1T1y-1W8P97GvX1M6PTj--MnrFQY8zQLReCHCmWdMaYUTVZbkjDOZaR6aED1FhpNrHmqlTaxVIFQupaE895nCEIjyiBoZot1rsJ1gkBFNYPvDwWz-ZTzDiITfU_4GXiwSv0_ZaRP3WtoZXMYLzypAhV7897R4Ida9cE7bTn_T2_9zw92BW33QTd53o-QubJnyHuzOO9butUuON0lotUt2yXzD572-D0XH8EyqnBTNEh-X8ld1ZlySV1XmEllmxDTfykKTTmWMVCXBsJoseivfMZC3llsD55XVRy0LRbBgl4S6JvVK2e2w-gF8vZJmeAiTsirNYyAiCqUQRsQypixLlAiiTPKEylxFOZXSgWAASKp7-narInKWjsTTLahSBFXagiqNHXgzfrPoyEsuLb0zACjtHVmdbtDjwMvxNboge64kS1Ot2jKhldEKmAOPOryOv8PVgyWD5Q64A4A3xv9dlyeX1-UF3EAMp58PZ0dP4SZtx5EdTjswaZYr8wyu6_OmqJfP-zFJ4PSq0fwH2fZ1uA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+itraconazole%2C+food%2C+and+ethnic+origin+on+the+pharmacokinetics+of+ivosidenib+in+healthy+subjects&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=Dai%2C+David&rft.au=Yang%2C+Hua&rft.au=Nabhan%2C+Salah&rft.au=Liu%2C+Hua&rft.date=2019-08-01&rft.pub=Springer+Nature+B.V&rft.issn=0031-6970&rft.eissn=1432-1041&rft.volume=75&rft.issue=8&rft.spage=1099&rft.epage=1108&rft_id=info:doi/10.1007%2Fs00228-019-02673-6&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon |